The Cooley’s Anemia Foundation is initiating an educational incentive awards program for children of U.S. individuals with severe thalassemia to further their education and career goals. These awards will be given in March 2025 for students enrolled in the fall 2024 and/or spring 2025 semester(s). The total amount of funding for this program for the […]
The Cooley’s Anemia Foundation sponsors patient incentive awards for those affected by thalassemia to further their education and career goals. These awards will be given in March 2025. The purpose of these Incentive Awards is to inspire patients to further their education and career goals and to help them live positively with thalassemia. Requirements: Some […]
The Cooley’s Anemia Foundation (CAF) is offering support for significant travel to treatment centers for thalassemia patients. CAF offers limited financial assistance to individuals with thalassemia who experience financial hardship due to travel expenses incurred in obtaining an annual comprehensive care evaluation or extraordinary thalassemia care at a major treatment center. (Extraordinary thalassemia care shall […]
The Cooley’s Anemia Foundation is announcing support for health maintenance in thalassemia patients 50 years & older. We are recognizing the importance of maintaining health among thalassemia patients and is offering reimbursement of up to $500 for approved expenses related to health maintenance among U.S. thalassemia patients who are age 50 or older. What expenses […]
We’re proud to announce five new Cooley’s Anemia Foundation Medical Research Fellowships for the 2024-2025 grant cycle. The total amount of funding for the research Fellowships is $250,000. These Fellowship recipients were assessed on the basis of the quality of the scientific content, the academic accomplishments and future promise of the investigator, the quality of […]
*IMPORTANT: The following information is a press release that has been released in advance of the date being presented for peer review* Agios Pharmaceuticals announced Monday that its drug Pyrukynd (mitapivat), an oral pyruvate kinase activator, reached its primary endpoint in a Phase III trial evaluating adults with the blood disorder transfusion-dependent alpha- or beta-thalassemia. […]
Here are a list of Care Walk Locations! Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Funds raised support medical research to fight thalassemia, a genetic blood disorder, as well as patient support services for thalassemia patients across the country. Your Walk, Your Way, […]
The Cooley’s Anemia Foundation is pleased to announce that the 2024 Patient-Family Conference will be held from July 12-14 at the Renaissance Concourse Atlanta Airport Hotel. During registration, you will have the option to choose whether you would like to attend in person or virtually. If you choose to attend virtually, only the sessions on […]
Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Funds raised support medical research to fight thalassemia, a genetic blood disorder, as well as patient support services for thalassemia patients across the country. Click here to register for Care Walk!! […]
The FDA has approved Vertex and CRISPR’s gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology. Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval […]
